Literature DB >> 28221194

Multiple Time-Point 68Ga-PSMA I&T PET/CT for Characterization of Primary Prostate Cancer: Value of Early Dynamic and Delayed Imaging.

Sebastian Schmuck1, Martin Mamach, Florian Wilke, Christoph A von Klot, Christoph Henkenberens, James T Thackeray, Jan M Sohns, Lilli Geworski, Tobias L Ross, Hans-Juergen Wester, Hans Christiansen, Frank M Bengel, Thorsten Derlin.   

Abstract

PURPOSE: The aims of this study were to gain mechanistic insights into prostate cancer biology using dynamic imaging and to evaluate the usefulness of multiple time-point Ga-prostate-specific membrane antigen (PSMA) I&T PET/CT for the assessment of primary prostate cancer before prostatectomy.
METHODS: Twenty patients with prostate cancer underwent Ga-PSMA I&T PET/CT before prostatectomy. The PET protocol consisted of early dynamic pelvic imaging, followed by static scans at 60 and 180 minutes postinjection (p.i.). SUVs, time-activity curves, quantitative analysis based on a 2-tissue compartment model, Patlak analysis, histopathology, and Gleason grading were compared between prostate cancer and benign prostate gland.
RESULTS: Primary tumors were identified on both early dynamic and delayed imaging in 95% of patients. Tracer uptake was significantly higher in prostate cancer compared with benign prostate tissue at any time point (P ≤ 0.0003) and increased over time. Consequently, the tumor-to-nontumor ratio within the prostate gland improved over time (2.8 at 10 minutes vs 17.1 at 180 minutes p.i.). Tracer uptake at both 60 and 180 minutes p.i. was significantly higher in patients with higher Gleason scores (P < 0.01). The influx rate (Ki) was higher in prostate cancer than in reference prostate gland (0.055 [r = 0.998] vs 0.017 [r = 0.996]).
CONCLUSIONS: Primary prostate cancer is readily identified on early dynamic and static delayed Ga-PSMA ligand PET images. The tumor-to-nontumor ratio in the prostate gland improves over time, supporting a role of delayed imaging for optimal visualization of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28221194     DOI: 10.1097/RLU.0000000000001589

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  23 in total

1.  PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer.

Authors:  Thorsten Derlin; Sebastian Schmuck; Cathleen Juhl; Johanna Zörgiebel; Sophie M Schneefeld; Almut C A Walte; Katja Hueper; Christoph A von Klot; Christoph Henkenberens; Hans Christiansen; James T Thackeray; Tobias L Ross; Frank M Bengel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-07       Impact factor: 9.236

2.  Inguino-scrotal bladder hernia: an unexpected finding on 68Ga-PSMA-11 PET/CT.

Authors:  Shirin Shahlaei; Sara Shakeri; Fatemeh Farahmandfar; Farshad Emami; Ramin Sadeghi
Journal:  Asia Ocean J Nucl Med Biol       Date:  2020

Review 3.  Advances in prostate-specific membrane antigen PET of prostate cancer.

Authors:  Kirsten Bouchelouche; Peter L Choyke
Journal:  Curr Opin Oncol       Date:  2018-05       Impact factor: 3.645

Review 4.  The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer.

Authors:  Yishen Wang; Joao R Galante; Athar Haroon; Simon Wan; Asim Afaq; Heather Payne; Jamshed Bomanji; Sola Adeleke; Veeru Kasivisvanathan
Journal:  Nat Rev Urol       Date:  2022-07-04       Impact factor: 16.430

5.  [68Ga-PSMA-I&T PET/CT for assessment of tumor burden in primary lesions of treatmentnaïve prostate cancer].

Authors:  Y Xie; C Li; L Zhang; S Zang; F Yu; S Wang; F Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-08-20

Review 6.  Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.

Authors:  Yundong He; Weidong Xu; Yu-Tian Xiao; Haojie Huang; Di Gu; Shancheng Ren
Journal:  Signal Transduct Target Ther       Date:  2022-06-24

7.  Imaging Characteristics and First Experience of [68Ga]THP-PSMA, a Novel Probe for Rapid Kit-Based Ga-68 Labeling and PET Imaging: Comparative Analysis with [68Ga]PSMA I&T.

Authors:  Thorsten Derlin; Sebastian Schmuck; Cathleen Juhl; Steffi Teichert; Johanna Zörgiebel; Hans-Jürgen Wester; Sophie M Schneefeld; Almut C A Walte; James T Thackeray; Tobias L Ross; Frank M Bengel
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

8.  Optimal time-point for 68Ga-PSMA-11 PET/CT imaging in assessment of prostate cancer: feasibility of sterile cold-kit tracer preparation?

Authors:  Mohsen Beheshti; Zeinab Paymani; Joana Brilhante; Hans Geinitz; Daniela Gehring; Thomas Leopoldseder; Ludovic Wouters; Christian Pirich; Wolfgang Loidl; Werner Langsteger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-23       Impact factor: 9.236

9.  Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis.

Authors:  Ian Leigh Alberts; Svenja Elizabeth Seide; Clemens Mingels; Karl Peter Bohn; Kuangyu Shi; Helle D Zacho; Axel Rominger; Ali Afshar-Oromieh
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-06       Impact factor: 9.236

10.  Biphasic GA 68-labeled prostate specific membrane antigen-11 positron emission tomography/computed tomography scans in the differential diagnosis and risk stratification of initial primary prostate cancer.

Authors:  Lu-Ping Qin; Jie Lv; Ming-Zhao Li; Liang-Jun Xie; Jin-Ping Li; Jian-Fang Li; Mu-Hua Cheng
Journal:  Quant Imaging Med Surg       Date:  2021-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.